Then, of course, there’s the M3 CSL, the best version of everyone’s favourite 3 Series. It was notable even in an ...

CSL shares have dropped 28% amid investor concerns over short-term revenue shortfalls and upcoming challenges like US pharmaceutical tariffs. Despite recent struggles, CSL's long-term growth remains ...

CSL Ltd (ASX: CSL) has seen significant growth with its share price rising by 130% over the last ten years. Its dividend yield has increased following recent share price declines. UBS predicts steady ...

CSL Ltd (ASX: CSL) shares have had a rough run this year. The biotech giant ended last week at $212.47, meaning its share price has tumbled about 28% over the past year. For a company long viewed as ...

Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

Sanofi’s $1.7 billion rare disease bet from last year has delivered a phase 2 win. In a midstage study, efdoralprin alfa beat the standard of care on primary and key secondary endpoints, positioning ...

CSL has FDA approval for its new drug to prevent hereditary angioedema (HAE) attacks, Andembry, offering a new, first-in-class option for patients with the rare genetic disorder. Factor XIIa inhibitor ...

(Reuters) -Australian biotech CSL said on Tuesday it no longer expects to complete the spin-off of its vaccine division in fiscal 2026, citing heightened volatility in the U.S. influenza vaccine ...

If at first you don’t succeed, try, try again. Set to send the ball back to Glenbrook South leading 7-0, senior punter Henry Hughes called for the snap. Instead, the spiraling pigskin landed in the ...

Ryan de Villiers is a budding automotive journalist based in South Africa and serving as one of the newest additions to the CarBuzz team. He immediately pursued a career in journalism after finishing ...